James W Jefferson

Summary

Affiliation: Healthcare Technology Systems
Country: USA

Publications

  1. ncbi request reprint Strategies for switching antidepressants to achieve maximum efficacy adolescents
    James W Jefferson
    Healthcare Technology Systems, Inc, Madison Institute of Medicine and the University of Wisconsin School of Medicine and Public Health, Madison, WI 53717, USA
    J Clin Psychiatry 69:14-8. 2008
  2. doi request reprint A clinician's guide to monitoring kidney function in lithium-treated patients
    James W Jefferson
    Department of Psychiatry, Healthcare Technology Systems, Inc, 7617 Mineral Point Rd, Ste 300, Madison, WI 53717, USA
    J Clin Psychiatry 71:1153-7. 2010
  3. doi request reprint Bupropion extended-release for depressive disorders
    James W Jefferson
    University of Wisconsin School of Medicine and Public Health, Madison Institute of Medicine, Inc, 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA
    Expert Rev Neurother 8:715-22. 2008
  4. ncbi request reprint Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study
    James W Jefferson
    Madison Institute of Medicine, Madison, WI 53717, USA
    J Clin Psychiatry 67:865-73. 2006
  5. ncbi request reprint Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
    James W Jefferson
    Madison Institute of Medicine and Department of Psychiatry, University of Wisconsin Medical School, 7617 Mineral Point Road, Madison, WI 53717, USA
    Clin Ther 27:1685-95. 2005
  6. ncbi request reprint Lamotrigine in psychiatry: pharmacology and therapeutics
    James W Jefferson
    Madison Institute of Medicine, Inc, Madison, WI 53717, USA
    CNS Spectr 10:224-32. 2005
  7. ncbi request reprint Old versus new medications: how much should be taught?
    James W Jefferson
    Madison Institute of Medicine, Inc, Wisconsin, USA
    Acad Psychiatry 29:162-6. 2005
  8. ncbi request reprint Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study
    Kenneth A Kobak
    Dean Foundation for Health, Research and Education, Middleton, Wisconsin, USA
    J Clin Psychopharmacol 22:257-62. 2002
  9. doi request reprint Teaching psychopharmacology: what works and what doesn't
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    J Clin Psychopharmacol 28:96-100. 2008
  10. doi request reprint Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology
    James C Mundt
    Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Ste 300, Madison, WI 53717, USA
    J Psychiatr Res 44:1224-8. 2010

Detail Information

Publications17

  1. ncbi request reprint Strategies for switching antidepressants to achieve maximum efficacy adolescents
    James W Jefferson
    Healthcare Technology Systems, Inc, Madison Institute of Medicine and the University of Wisconsin School of Medicine and Public Health, Madison, WI 53717, USA
    J Clin Psychiatry 69:14-8. 2008
    ..Each switch strategy has advantages and disadvantages, and the choice should be made based on the patient, the patient's illness, the medications involved, and clinical judgment...
  2. doi request reprint A clinician's guide to monitoring kidney function in lithium-treated patients
    James W Jefferson
    Department of Psychiatry, Healthcare Technology Systems, Inc, 7617 Mineral Point Rd, Ste 300, Madison, WI 53717, USA
    J Clin Psychiatry 71:1153-7. 2010
    ..This overview clarifies those practical aspects of monitoring that are often overlooked or misunderstood...
  3. doi request reprint Bupropion extended-release for depressive disorders
    James W Jefferson
    University of Wisconsin School of Medicine and Public Health, Madison Institute of Medicine, Inc, 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA
    Expert Rev Neurother 8:715-22. 2008
    ..This review provides a history of the evolution of bupropion in its three formulations, with an emphasis on the efficacy and tolerability of the extended-release preparation...
  4. ncbi request reprint Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study
    James W Jefferson
    Madison Institute of Medicine, Madison, WI 53717, USA
    J Clin Psychiatry 67:865-73. 2006
    ....
  5. ncbi request reprint Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
    James W Jefferson
    Madison Institute of Medicine and Department of Psychiatry, University of Wisconsin Medical School, 7617 Mineral Point Road, Madison, WI 53717, USA
    Clin Ther 27:1685-95. 2005
    ..Understanding the pharmacokinetic (PK) properties and formulations of bupropion can help optimize clinical use...
  6. ncbi request reprint Lamotrigine in psychiatry: pharmacology and therapeutics
    James W Jefferson
    Madison Institute of Medicine, Inc, Madison, WI 53717, USA
    CNS Spectr 10:224-32. 2005
    ..This review critically evaluates the support for lamotrigine use across a broad range of psychiatric disorders as well as discuss its pharmacology, side-effect profile, and interactions with other medications...
  7. ncbi request reprint Old versus new medications: how much should be taught?
    James W Jefferson
    Madison Institute of Medicine, Inc, Wisconsin, USA
    Acad Psychiatry 29:162-6. 2005
    ..To address the issue of how much psychiatric residents should be taught about older medications...
  8. ncbi request reprint Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study
    Kenneth A Kobak
    Dean Foundation for Health, Research and Education, Middleton, Wisconsin, USA
    J Clin Psychopharmacol 22:257-62. 2002
    ..Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found...
  9. doi request reprint Teaching psychopharmacology: what works and what doesn't
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    J Clin Psychopharmacol 28:96-100. 2008
    ....
  10. doi request reprint Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology
    James C Mundt
    Healthcare Technology Systems, Inc, 7617 Mineral Point Road, Ste 300, Madison, WI 53717, USA
    J Psychiatr Res 44:1224-8. 2010
    ....
  11. ncbi request reprint Psychiatric complications of deep brain stimulation for Parkinson's disease
    Shelley D Piasecki
    University of Wisconsin Psychiatric Institute and Clinics, Madison
    J Clin Psychiatry 65:845-9. 2004
    ....
  12. ncbi request reprint Comments on article by Harrigan et al: "A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition"
    James W Jefferson
    J Clin Psychopharmacol 24:456. 2004
  13. ncbi request reprint Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study
    Atul C Pande
    Pfizer Global Research and Development, New London, CT 06320, USA
    J Clin Psychopharmacol 24:141-9. 2004
    ..Somnolence and dizziness were the most frequently occurring adverse events among patients receiving pregabalin 600 mg/d. In conclusion, pregabalin 600 mg/d was an effective and well-tolerated treatment of social anxiety disorder...
  14. ncbi request reprint Is it easier to find what you are looking for if you think you know what it looks like?
    James C Mundt
    J Clin Psychopharmacol 27:121-5. 2007
  15. ncbi request reprint They could have named it "bupopion"
    James W Jefferson
    J Clin Psychiatry 64:849-50. 2003
  16. ncbi request reprint Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants
    Vimal M Aga
    J Clin Psychiatry 64:609-11. 2003
  17. ncbi request reprint It looks like "bradyphylaxis" to me
    James W Jefferson
    J Clin Psychiatry 66:1076; author reply 1076-7. 2005